PRACTICAL ONCOLOGY JOURNAL ›› 2010, Vol. 24 ›› Issue (1): 62-63.doi: 10.3969/j.issn.1002-3070.2010.01.016

Previous Articles     Next Articles

Clinical comparison of docetaxel/capecitabine and oxaliplatin/capecitabine in treating advanced gastric cancer

LIU Lei1, GU Manling2   

  1. 1.The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081;
    2.The Red Cross Central Hospital of Harbin,Harbin 150081
  • Received:2009-05-13 Online:2010-02-28 Published:2015-01-23

Abstract: Objective To evaluate the objective response rate,time to progression(TTP)and toxicity between Docetaxel/Capecitabine and Oxaliplatin/Capecitabine in the treatment of advanced gastric cancer.Methods 21 patients with advanced gastric cancer were administrated with Docetaxel 75mg/m2(d1),Capecitabine 1700mg/m2/d divided in two daily doses given from d1 to d14.The cycles were repeated every 21 days.All patients received two to six cycles.The other 20 patients with advanced gastric cancer were administrated with Oxaliplatin 130mg/m2,(d1)combined Capecitabine 1700mg/m2/d divided in two daily doses given from d1 to d14.All patients received two to six cycles.The treatment was finished after 2 recycles.Results The total response rate in Docetaxel/Capecitabine was 52.4 %,the most common adverse effects were febrile neutropeni,neutropenia,alopecia,diarrhea and inflammation of oral mucosa.The response rate in XELOX was 50.0 %,the most common adverse effects were hand foot syndrome and peripheral neuropathy.Conclusion The Oxaliplatin/Capecitabine regimen offers a better therapeutic option in patients with advanced gastric cancer.

CLC Number: